Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Neuromuscular Junction And Blockade01:29

Neuromuscular Junction And Blockade

The site of chemical communication between a motor neuron and a muscle fiber is called the neuromuscular junction (NMJ). The end of the motor neuron at the NMJ divides into a cluster of synaptic end bulbs. The cytoplasm of these bulbs consists of synaptic vesicles enclosing acetylcholine molecules, the principal neurotransmitter released at the NMJ. The region opposite the synaptic bulb that ends in the muscle fiber is called the motor end plate, which has acetylcholine receptors. Within the...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Paraneoplastic neuromuscular disorders-part 2.

Journal of clinical neuromuscular disease·2008
Same author

Orchiectomy for suspected microscopic tumor in patients with anti-Ma2-associated encephalitis.

Neurology·2006
Same author

Antiphospholipid and glutamic acid decarboxylase antibodies in patients with focal epilepsy.

Neurology·2004
Same author

Novel chemotherapeutic approaches to brain tumors.

Hematology/oncology clinics of North America·2002
Same author

Principles of paraneoplastic syndromes.

Annals of the New York Academy of Sciences·1998
Same author

Phase II study of intracarotid or selective intracerebral infusion of cisplatin for treatment of recurrent anaplastic gliomas.

Journal of neuro-oncology·1998

Related Experiment Video

Updated: Jun 27, 2026

Combined In Vivo Electroporation and Short-Term Reinnervation of the Cranial Levator Auris Longus Skeletal Muscle
04:44

Combined In Vivo Electroporation and Short-Term Reinnervation of the Cranial Levator Auris Longus Skeletal Muscle

Published on: November 1, 2024

Paraneoplastic neuromuscular disorders-part I.

E J Dropcho1

  • 1From the Department of Neurology Indiana University Medical Center, and the Neurology Service, Richard Roudebush Veterans Affairs Medical Center Indianapolis IN.

Journal of Clinical Neuromuscular Disease
|December 17, 2008
PubMed
Summary

Paraneoplastic disorders are rare cancer complications often linked to autoimmune issues. Early diagnosis of these neurological conditions improves patient outcomes.

More Related Videos

Stimulated Single Fiber Electromyography (SFEMG) for Assessing Neuromuscular Junction Transmission in Rodent Models
04:30

Stimulated Single Fiber Electromyography (SFEMG) for Assessing Neuromuscular Junction Transmission in Rodent Models

Published on: March 8, 2024

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
07:30

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

Published on: November 9, 2017

Related Experiment Videos

Last Updated: Jun 27, 2026

Combined In Vivo Electroporation and Short-Term Reinnervation of the Cranial Levator Auris Longus Skeletal Muscle
04:44

Combined In Vivo Electroporation and Short-Term Reinnervation of the Cranial Levator Auris Longus Skeletal Muscle

Published on: November 1, 2024

Stimulated Single Fiber Electromyography (SFEMG) for Assessing Neuromuscular Junction Transmission in Rodent Models
04:30

Stimulated Single Fiber Electromyography (SFEMG) for Assessing Neuromuscular Junction Transmission in Rodent Models

Published on: March 8, 2024

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
07:30

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

Published on: November 9, 2017

Area of Science:

  • Neurology
  • Oncology
  • Immunology

Background:

  • Paraneoplastic disorders are uncommon but significant complications of various neoplasms.
  • Many paraneoplastic syndromes are suspected to have an autoimmune origin, with varying evidence.
  • Early identification of paraneoplastic disorders is crucial for better neurologic and oncologic prognoses.

Purpose of the Study:

  • To review clinical features, autoimmune aspects, diagnosis, and treatment of paraneoplastic disorders affecting the central and peripheral nervous system.
  • To provide a comprehensive overview of paraneoplastic syndromes impacting the spinal cord, motor neurons, neuromuscular junction, and muscle.
  • To prepare for a subsequent review on paraneoplastic neuropathies.

Main Methods:

  • Literature review of paraneoplastic disorders.
  • Analysis of clinical presentations and diagnostic strategies.
  • Synthesis of current treatment options and autoimmune etiologies.

Main Results:

  • Paraneoplastic disorders manifest with diverse neurological symptoms.
  • Autoimmunity plays a significant role in the pathogenesis of many paraneoplastic syndromes.
  • Diagnostic challenges exist, requiring a multidisciplinary approach.

Conclusions:

  • Prompt diagnosis and management of paraneoplastic disorders are essential for improving patient outcomes.
  • Understanding the autoimmune basis is key to developing targeted therapies.
  • This review covers key aspects of paraneoplastic disorders affecting the nervous system, with a focus on Part 1.